In light of these molecular findings, together with its up-regulated oncogenic expression in human colorectal cancer tissues, the MortaparibPlus-mediated down-regulation of mortalin expression in colorectal cancer cells possessing a mutant p53 (as in the case of DLD-1 cells (p53S241F)) could provide a successful molecular therapeutic strategy. This evidence concerns the gene TP53 and colorectal cancer.